Results 111 to 120 of about 43,858 (197)

A Sensitive Electrochemical Sensor Based on Calix[n]arene-Modified PGE for the Determination of Tofacitinib in Human Urine Samples and Pharmaceutical Dosage Forms. [PDF]

ACS Omega
Sardohan Koseoglu T, Yalabik A, Koseoglu H.   +2 more
europepmc   +1 more source

A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost‐Effective: Results of the Multicentre IBD Value Study

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 3, Page 313-325, August 2026.
This study provides real‐world evidence that implementing an advanced therapy care pathway for patients with IBD leads to significant healthcare cost savings without compromising quality of life. These findings support broader implementation of care pathways in the management of patients with chronic conditions to optimise care delivery and resource ...
Elyke H. Visser, Martijn. A. Oude Voshaar, Reinier C. A. van Linschoten, Alexander G. L. Bodelier, Claire Fitzpatrick, Vincent de Jonge, Hestia Vermeulen, K. Evelyne Verweij, Sanne van der Wiel, Daniëlle van der Horst, C. Janneke van der Woude, R. L. West, D. van Noord   +12 more
wiley   +1 more source

Tofacitinib: New drug in the therapeutic armamentarium in ocular inflammation. [PDF]

Indian J Ophthalmol
Babu K, Mooss V.
europepmc   +1 more source

Application of Systems Genetics to Investigate Molecular Pathology of Early‐Onset Colorectal Cancer

Chemical Biology &Drug Design, Volume 108, Issue 2, August 2026.
Early‐onset colorectal cancer (EOCRC) presents a complex molecular landscape that requires integrated multi‐omics approaches. This article reviews current applications of systems genetics in EOCRC research and provides a step‐by‐step protocol for network‐based analyses featuring PIK3CA to demonstrate practical application for researchers of all levels.
Minjae J. Kim, Sydney L. Carr, Vishnutheertha Kulkarni, Mary‐Louise Manchadi   +3 more
wiley   +1 more source

An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patients. [PDF]

Ther Adv Gastroenterol
Tursi A, Pasta A, Elisei W, Barberio B, Bertin L, Mocci G, Maconi G, Gravina AG, Pellegrino R, Bodini G, Papa A, Savarino EV, Italian Network for Inflammatory Bowel Diseases (IN-IBD).   +12 more
europepmc   +1 more source

S3‐Leitlinie Diagnostik und Therapie der Alopecia areata – Teil 2: Therapie, psychosoziale und kosmetische Unterstützung

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page 1155-1179, August 2026.
Zusammenfassung In diesem zweiten Teil der S3‐Leitlinie zur Diagnostik und Therapie der Alopecia areata (AA) stellen wir die zentralen Inhalte und Empfehlungen zur topischen und systemischen Therapie, zur Lebensqualität und zu Unterstützungsangeboten vor.
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

Successful Treatment of Anti-Jo-1 Positive Inflammatory Myopathy With Tofacitinib. [PDF]

Case Rep Rheumatol
Timsans J, Hokkanen AM, Rautavaara J, Kerola A, Huovinen S, Kauppi M.   +5 more
europepmc   +1 more source

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page e1155-e1177, August 2026.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

JAK/STAT inhibition reprograms T cell activation and metabolism in inflammatory arthritis patients. [PDF]

Inflamm Res
Marzaioli V, Brugman AAI, O'Dowd N, Floudas A, Gorman A, Orr C, Veale DJ, Fearon U.   +7 more
europepmc   +1 more source

The TG2/LRP1 Pathway for T Cell Activation by Post‐Translationally Modified Antigens

Immunological Reviews, Volume 341, Issue 1, August 2026.
ABSTRACT Post‐translational modifications (PTMs) can generate neo‐epitopes, modified peptides that evade immune tolerance and trigger immune responses. This review focuses on the TG2/LRP1 pathway as a new paradigm for coupling the formation of post‐translationally modified peptides with their effective presentation as T‐cell antigens by dendritic cells.
Agnele Sylvia Sewa, Fu‐Chen Yang, Chaitan Khosla   +2 more
wiley   +1 more source